The Study Of Drug Resistance Ratios And Associated Factors For Pseudomonas Aeruginosa Bacteria

Objective: To explore the drug resistance status of Pseudomonas aeruginosa for reasonable use of antibiotics and for preventing the infections of resistant Pseudomonas aeruginosa. Methods: (1) Pseudomonas aeruginosa from sputum cultures in patients from some hospital on the year 2005 was isolated with VITEK GNI+ automation system. (2) The possible risk factors, which were associated with the drug resistance status, such as the basis of the disease ,hospital departments and the use of antibiotics, were investigated by reviewing patients' medical records.(3) Forward stepwise multiple logistic regression models were used for statistical analyses. Results: The patients infected with Pseudomonas aeruginosa mainly exists in wards of breath branch, neurosurgery, nerveinternal medicine department and ICU, these patients account for 82.56% in total. The resistant ratios to seven common usable antibiotics rank from 68.5% to 38.5 %. Ceftazidime have the lowest resistant rate (38.5%), Imipenem have the secondary resistant rate (45.9%). The resistant ratios to amikacin,cefoperazone /sulbactam were 50.5% and 59.0% respectively. The resistant ratios to Aztreonam, Ciprofloxacin and Iperacillin/tazobactam were even higher (63.2%. 67.3% and 68.5%, respectively). Multiple logistic regression analyses showed : Different wards, using breathing machine, days before infection in hospital and gender were associated with the sensitivities to seven common usable antibiotics for Pseudomonas aeruginosa. Conclusion: (1) Ceftazidime can first be chosen to treat the patients infected with pseudomonas aeruginosa..(2) In order to Prevent and reduce the drug resistant ratios for Pseudomonas aeruginosa, we should pay more attention to the patients stayed at words of nerveintemal medicine department and ICU. (3)Many risk factors, such as days in hospital, being in different wards, using a breathing machine, using the third-generation cephalosporins.and Imipenem-Cilastatin, were associated with the drug resistant ratios for Pseudomonas aeruginosa.